Bone Biologics Corp Files 8-K for Material Definitive Agreement
Ticker: BBLGW · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $100,000, $5,000, $2,500, $1,143,121 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
Related Tickers: BBLG
TL;DR
BBLG just signed a big deal, details TBD.
AI Summary
On September 27, 2024, Bone Biologics Corporation entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as parties involved or financial terms, but indicates it is a significant event for the company.
Why It Matters
This filing signals a significant development for Bone Biologics Corp, potentially impacting its strategic direction, financial health, or operational activities.
Risk Assessment
Risk Level: medium — The lack of specific details in the 8-K filing regarding the material definitive agreement introduces uncertainty and potential risk for investors.
Key Players & Entities
- Bone Biologics Corporation (company) — Registrant
- September 27, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Bone Biologics Corporation?
The filing does not specify the nature of the material definitive agreement, only that one was entered into on September 27, 2024.
Who are the parties involved in this material definitive agreement?
The filing does not disclose the names of the other parties involved in the agreement.
Are there any financial terms or obligations associated with this agreement?
The filing does not provide any details regarding financial terms or obligations related to the agreement.
What is the expected impact of this agreement on Bone Biologics Corporation's business operations?
The filing does not detail the expected impact of the agreement on the company's business operations.
When was this material definitive agreement officially entered into?
The earliest event reported, which includes the entry into the material definitive agreement, is dated September 27, 2024.
Filing Stats: 1,043 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-09-27 17:05:28
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
- $100,000 — he Agreement in an amount not to exceed $100,000 in the aggregate, in addition to $5,000
- $5,000 — 00,000 in the aggregate, in addition to $5,000 per annual due diligence session update
- $2,500 — ompany's Annual Report on Form 10-K and $2,500 per quarterly due diligence update sess
- $1,143,121 — ares having an aggregate sales price of $1,143,121 and (ii) the termination of the Agreeme
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex1-1.htm (EX-1.1) — 263KB
- ex5-1.htm (EX-5.1) — 17KB
- ex5-1_001.jpg (GRAPHIC) — 29KB
- ex5-1_002.jpg (GRAPHIC) — 21KB
- 0001493152-24-038583.txt ( ) — 684KB
- bblg-20240927.xsd (EX-101.SCH) — 4KB
- bblg-20240927_def.xml (EX-101.DEF) — 29KB
- bblg-20240927_lab.xml (EX-101.LAB) — 36KB
- bblg-20240927_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: September 27, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer